Clinical Trial

FUnctional Selection of Advanced Breast Cancer Patients for Talazoparib Treatment Using the REpair Capacity (RECAP) Test

Study acronym: FUTURE
Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated February 28, 2025 (before its estimated December 2025 completion). Its status may not reflect the trial's current state.
Summary
The goal of this clinical trial is to prove that the RECAP test is capable of selecting advanced breast cancer patients sensitive for treatment with the PARP inhibitor talazoparib. Participants will undergo an ultrasound-guided biopsy and a blood withdrawal. Homologous Recombination (HR) deficient patients (approximately 30%) can start talazoparib treatment until progression of the disease or unacceptable side-effects and their response will be evaluated.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2023-12-20.
Trial Details
NCT Number NCT06193525
Lead Sponsor Erasmus Medical Center
Collaborators: Leiden University Medical Center, University Medical Center Groningen
Conditions Advanced Breast Cancer
Enrollment 66 participants
Start Date 2019-09-16
Primary Completion 2025-12 (estimated)
Study Completion 2025-12 (estimated)
Updated on ClinicalTrials.gov 2025-02-28